Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA/SEC Regulatory Coordination Talks Await New Securities Chairman

Executive Summary

FDA and the Securities & Exchange Commission are deferring discussions about ideas for closer cooperation pending the appointment of a new SEC chairman

You may also be interested in...



FDA/SEC Cooperation On Investor Communications To Be Headed By Taylor

FDA Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison with the Securities & Exchange Commission as FDA expands its role in regulating investor communications

FDA/SEC Cooperation On Investor Communications To Be Headed By Taylor

FDA Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison with the Securities & Exchange Commission as FDA expands its role in regulating investor communications

SEC’s Busy Week: Schering Notified Of Potential Suit; Waksal Expands Plea

SEC's crackdown on corporate accounting and investor communications is reaching deeper into the pharmaceutical sector

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040867

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel